Effect of filgrastim (G-CSF) in hodgkin's disease patients treated with radiation therapy

Susan J. Knox, Sherry Fowler, Carol Marquez, Richard T. Hoppe

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: To evaluate the effect of filgrastim (recombinant human G-CSF) on radiation-induced neutropenia in a well defined, homogenous patient population. Methods and Materials: Seven patients who were to receive large field subdisphragmatic irradiation after thoracic "mantle" fields for treatment of Hodgkin's disease entered this study. They received daily subcutaneous (SC) injections of filgrastim during subdiaphragmatic irradiation. Total white blood cell (WBC) and absolute neutrophil cell (ANC) counts were measured and compared to a historical series of patients, and hematological toxicity was assessed. The endpoints of the study were nadir WBC and ANC counts and time to WBC and ANC recovery. Results: Compared to the historical series, filgrastim significantly increased the WBC and ANC throughout the period of subdiaphragmatic irradiation. Nadir WBC ( 5.98 + - 1.24/mm3) and ANC ( 4.71 + - 1.07/mm3) in the Filgrastim group were approximately two times those of the historical series ( 3.32 + - 1.06/mm3 and 2.39 + -0.9/mm3 respectively; p <0.002). Nadir platelet counts were not affected by filgrastim therapy. Three of seven patients reported mild musculoskeletal pain, but there was no other apparent toxicity. Conclusion: Compared to the historical series, filgrastim therapy significantly increased WBC and ANC during extended field radiation therapy and was well tolerated. It may be clinically useful in other groups of patients who are likely to develop profound neutropenia during large field irradiation.

Original languageEnglish (US)
Pages (from-to)445-450
Number of pages6
JournalInternational journal of radiation oncology, biology, physics
Volume28
Issue number2
DOIs
StatePublished - Jan 15 1994
Externally publishedYes

Fingerprint

neutrophils
leukocytes
Granulocyte Colony-Stimulating Factor
Hodgkin Disease
radiation therapy
Neutrophils
Leukocytes
Radiotherapy
cells
irradiation
Neutropenia
toxicity
therapy
Cell Count
Musculoskeletal Pain
pain
Subcutaneous Injections
platelets
Platelet Count
Filgrastim

Keywords

  • Filgrastim (G-CSF)
  • Growth factor
  • Hodgkin's disease
  • Myelosuppression
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Effect of filgrastim (G-CSF) in hodgkin's disease patients treated with radiation therapy. / Knox, Susan J.; Fowler, Sherry; Marquez, Carol; Hoppe, Richard T.

In: International journal of radiation oncology, biology, physics, Vol. 28, No. 2, 15.01.1994, p. 445-450.

Research output: Contribution to journalArticle

Knox, Susan J. ; Fowler, Sherry ; Marquez, Carol ; Hoppe, Richard T. / Effect of filgrastim (G-CSF) in hodgkin's disease patients treated with radiation therapy. In: International journal of radiation oncology, biology, physics. 1994 ; Vol. 28, No. 2. pp. 445-450.
@article{4d88712f1f664431a23fe8415b0e19cd,
title = "Effect of filgrastim (G-CSF) in hodgkin's disease patients treated with radiation therapy",
abstract = "Purpose: To evaluate the effect of filgrastim (recombinant human G-CSF) on radiation-induced neutropenia in a well defined, homogenous patient population. Methods and Materials: Seven patients who were to receive large field subdisphragmatic irradiation after thoracic {"}mantle{"} fields for treatment of Hodgkin's disease entered this study. They received daily subcutaneous (SC) injections of filgrastim during subdiaphragmatic irradiation. Total white blood cell (WBC) and absolute neutrophil cell (ANC) counts were measured and compared to a historical series of patients, and hematological toxicity was assessed. The endpoints of the study were nadir WBC and ANC counts and time to WBC and ANC recovery. Results: Compared to the historical series, filgrastim significantly increased the WBC and ANC throughout the period of subdiaphragmatic irradiation. Nadir WBC ( 5.98 + - 1.24/mm3) and ANC ( 4.71 + - 1.07/mm3) in the Filgrastim group were approximately two times those of the historical series ( 3.32 + - 1.06/mm3 and 2.39 + -0.9/mm3 respectively; p <0.002). Nadir platelet counts were not affected by filgrastim therapy. Three of seven patients reported mild musculoskeletal pain, but there was no other apparent toxicity. Conclusion: Compared to the historical series, filgrastim therapy significantly increased WBC and ANC during extended field radiation therapy and was well tolerated. It may be clinically useful in other groups of patients who are likely to develop profound neutropenia during large field irradiation.",
keywords = "Filgrastim (G-CSF), Growth factor, Hodgkin's disease, Myelosuppression, Radiation therapy",
author = "Knox, {Susan J.} and Sherry Fowler and Carol Marquez and Hoppe, {Richard T.}",
year = "1994",
month = "1",
day = "15",
doi = "10.1016/0360-3016(94)90069-8",
language = "English (US)",
volume = "28",
pages = "445--450",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of filgrastim (G-CSF) in hodgkin's disease patients treated with radiation therapy

AU - Knox, Susan J.

AU - Fowler, Sherry

AU - Marquez, Carol

AU - Hoppe, Richard T.

PY - 1994/1/15

Y1 - 1994/1/15

N2 - Purpose: To evaluate the effect of filgrastim (recombinant human G-CSF) on radiation-induced neutropenia in a well defined, homogenous patient population. Methods and Materials: Seven patients who were to receive large field subdisphragmatic irradiation after thoracic "mantle" fields for treatment of Hodgkin's disease entered this study. They received daily subcutaneous (SC) injections of filgrastim during subdiaphragmatic irradiation. Total white blood cell (WBC) and absolute neutrophil cell (ANC) counts were measured and compared to a historical series of patients, and hematological toxicity was assessed. The endpoints of the study were nadir WBC and ANC counts and time to WBC and ANC recovery. Results: Compared to the historical series, filgrastim significantly increased the WBC and ANC throughout the period of subdiaphragmatic irradiation. Nadir WBC ( 5.98 + - 1.24/mm3) and ANC ( 4.71 + - 1.07/mm3) in the Filgrastim group were approximately two times those of the historical series ( 3.32 + - 1.06/mm3 and 2.39 + -0.9/mm3 respectively; p <0.002). Nadir platelet counts were not affected by filgrastim therapy. Three of seven patients reported mild musculoskeletal pain, but there was no other apparent toxicity. Conclusion: Compared to the historical series, filgrastim therapy significantly increased WBC and ANC during extended field radiation therapy and was well tolerated. It may be clinically useful in other groups of patients who are likely to develop profound neutropenia during large field irradiation.

AB - Purpose: To evaluate the effect of filgrastim (recombinant human G-CSF) on radiation-induced neutropenia in a well defined, homogenous patient population. Methods and Materials: Seven patients who were to receive large field subdisphragmatic irradiation after thoracic "mantle" fields for treatment of Hodgkin's disease entered this study. They received daily subcutaneous (SC) injections of filgrastim during subdiaphragmatic irradiation. Total white blood cell (WBC) and absolute neutrophil cell (ANC) counts were measured and compared to a historical series of patients, and hematological toxicity was assessed. The endpoints of the study were nadir WBC and ANC counts and time to WBC and ANC recovery. Results: Compared to the historical series, filgrastim significantly increased the WBC and ANC throughout the period of subdiaphragmatic irradiation. Nadir WBC ( 5.98 + - 1.24/mm3) and ANC ( 4.71 + - 1.07/mm3) in the Filgrastim group were approximately two times those of the historical series ( 3.32 + - 1.06/mm3 and 2.39 + -0.9/mm3 respectively; p <0.002). Nadir platelet counts were not affected by filgrastim therapy. Three of seven patients reported mild musculoskeletal pain, but there was no other apparent toxicity. Conclusion: Compared to the historical series, filgrastim therapy significantly increased WBC and ANC during extended field radiation therapy and was well tolerated. It may be clinically useful in other groups of patients who are likely to develop profound neutropenia during large field irradiation.

KW - Filgrastim (G-CSF)

KW - Growth factor

KW - Hodgkin's disease

KW - Myelosuppression

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0028115686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028115686&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(94)90069-8

DO - 10.1016/0360-3016(94)90069-8

M3 - Article

VL - 28

SP - 445

EP - 450

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -